Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 11/20 | 0.57 |
| ▸ | NQO2 | P16083 | 1/20 | 0.40 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.40 |
| ▸ | WNT1 | P04628 | 2/20 | 0.40 |
| ▸ | GSK3B | P49841 | 2/20 | 0.40 |
| ▸ | TTK | P33981 | 1/20 | 0.39 |
| ▸ | CLK2 | P49760 | 2/20 | 0.38 |
| ▸ | CLK3 | P49761 | 2/20 | 0.38 |
| ▸ | IRAK1 | P51617 | 4/20 | 0.38 |
| ▸ | IRAK4 | Q9NWZ3 | 4/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12547210 | 0.86 | MET (0.56) | MET | |
| SCHEMBL12547564 | 0.84 | MET (0.61) | METIRAK1IRAK4 | |
| SCHEMBL1952590 | 0.81 | MET (0.55) | METIRAK1IRAK4 | |
| SCHEMBL3091030 | 0.79 | MET (0.62) | METNQO2 | |
| SCHEMBL12547542 | 0.78 | MET (0.56) | MET | |
| SCHEMBL12547736 | 0.77 | MET (0.58) | METNQO2IRAK1IRAK4 | |
| SCHEMBL12547422 | 0.76 | MET (0.56) | METNQO2 | |
| SCHEMBL12547718 | 0.75 | MET (0.49) | METIRAK1 | |
| SCHEMBL12547561 | 0.74 | MET (0.57) | METNQO2 | |
| SCHEMBL12547481 | 0.74 | MAP4K1 (0.44) | METNQO2DYRK1AWNT1GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8435986-B2 | Bicyclic traizole derivatives for treating of tumors | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2013-05-07 | — | — | US | disclosed |
| US-20110135600-A1 | BICYCLIC TRAIZOLE DERIVATIVES FOR TREATING OF TUMORS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG | 2011-06-09 | — | — | US | disclosed |
| US-20110135600-A1 | BICYCLIC TRAIZOLE DERIVATIVES FOR TREATING OF TUMORS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG | 2011-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110135600-A1 | BICYCLIC TRAIZOLE DERIVATIVES FOR TREATING OF TUMORS | RET, BMX, ERBB2 | MET 11/4885NQO2 2664/4885DYRK1A 100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.